Abbott Laboratories downgraded at JP Morgan
ABT was downgraded from Overweight to Neutral, JP Morgan said. Valuation call, as the stock has outperformed its peers year-to-date.
-----
Accenture estimates lowered at Citigroup
ACN estimates lowered through 2012, Citigroup said. Small adjustments due to negative FX moves. Maintain $66 price target and Buy rating.
-----
Accretive Health rated new Buy at UBS
AH was initiated with a Buy rating, UBS said. $29 price target. Riding healthcare tailwinds to address a large market opportunity.
-----
Alexion Pharmaceuticals numbers raised at Oppenheimer
Shares of ALXN now seen reaching $74, according to Oppenheimer. Estimates also increased, as Solaris should continue to drive growth. Outperform rating.
-----
AMC Networks rated new Sell at Stifel
AMCX was initiated with a Sell rating, Stifel Nicolaus said. Valuation call, based on a $30 price target.
-----
Baxter upgraded at JP Morgan
BAX was upgraded from Neutral to Overweight, JP Morgan said. Sales growth should accelerate over the next several quarters.
-----
Boston Scientific upgraded at JP Morgan
BSX was upgraded from Underweight to Neutral, JP Morgan said. Valuation call, as the stock is down 34% since last January. Company sports an attractive 13% free cash flow yield.
-----
Bunge Limited upgraded at Citigroup
BG was upgraded from Hold to Buy, Citigroup said. $88 price target. See significant value following the 24% decline over the past two months.
-----
Clorox upgraded at Caris
CLX was upgraded from Below Average to Average, Caris & Company said. $66 price target. Stock is attractive, following the Icahn-related selloff.
-----
Corn Products International estimates, target cut at Citigroup
Shares of CPO now seen reaching $68, according to Citigroup. Estimates also lowered on FX headwinds. Maintain Buy rating.
-----
Dollar Tree numbers increased at Morgan Stanley
DLTR estimates were raised through 2014, Morgan Stanley said. Company should continue to grow square footage and see better store traffic over the next several quarters. Overweight rating and new $86 price target.
-----
EMC target reduced at Morgan Stanley
Shares of EMC now seen reaching $33, according to Morgan Stanley. Macro weakness could hurt IT spending. In addition, the company is facing increased competition. Overweight rating.
-----
F5 Networks rated new Hold at Jefferies
Coverage of FFIV was started with a Hold rating, Jefferies said. Valuation call, based on a $70 price target.
-----
Freescale Semiconductor estimates lowered at Credit Suisse
FSL estimates were cut through 2012, Credit Suisse said. Company is seeing weaker industrial and networking demand. Outperform rating and $27 price target.
-----
Gartner rated new Neutral at Goldman
IT was initiated with a Neutral rating, Goldman Sachs said. $35 price target. Macro headwinds could hurt near-term growth.
-----
Genesis Energy upgraded at UBS
GEL was upgraded from Neutral to Buy, UBS said. $27 price target. Valuation call, along with strong financial metrics.
-----
Holly Energy upgraded at UBS
HEP was upgraded from Neutral to Buy, UBS said. $55 price target. Attractive valuation for stable business.
-----
Hunstman cut from Conviction Buy List at Goldman
HUN was removed from the Conviction Buy list, Goldman Sachs said. Estimates also lowered, as the sector is facing lower demand and currency/commodity headwinds. New $14 price target.
-----
Legg Mason numbers cut at Jefferies
Shares of LM now seen reaching $31, according to Jefferies. Estimates also reduced, given higher market volatility. Buy rating.
-----
Maximus rated new Market Outperform at JMP
MMS was initiated with a Market Perform rating, JMP Securities said. $41 price target. Company can continue to grow across the globe.
-----
Precision Drilling rated new Outperform at Credit Suisse
Coverage of PDS was started with an Outperform rating, Credit Suisse said. $16 price target. Canadian operations should drive growth over the next several quarters.
-----
Riverbed Technology rated new Underperform at Jefferies
RVBD was initiated with an Underperform rating, Jefferies said. $15 price target. WAN optimization market should see decelerating growth.
-----
Stryker upgraded at JP Morgan
SYK was upgraded to Overweight, JP Morgan said. Valuation call, as the stock is down 12% year-to-date.
-----
Vera Bradley rated new Buy at Jefferies
VRA was initiated with a Buy rating, Jefferies said. $50 price target. Company is still in the early stages of an attractive growth opportunity.
-----
WMS Industries downgraded at Sterne Agee
WMS was downgraded from Buy to Neutral, Sterne Agee said. $22 price target. Company lacks near-term catalysts.
-----
Zimmer downgraded at JP Morgan
ZMH was downgraded to Neutral, JP Morgan said. Company will likely see slower growth in the coming quarters/
